Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis

Fig. 3

Proportion of patients achieving MCID in WPAI through week 12/ET. MCID for WPAI was defined as ≥7% decrease from baseline. Except for “daily activity impairment,” only full-time paid workers and part-time paid workers were included (not homemakers). All time points except for week 12/ET are observed data. At week 12/ET, last observation carried forward was used for missing scores. p values calculated using the chi-squared test (RAJ3) or Fisher’s exact test (RAJ4), with no adjustment made for multiplicity. *p<0.05; **p<0.01; ***p<0.001, peficitinib versus placebo. p value not estimable (RAJ3 only) in absenteeism at any time point, or presenteeism and loss of work productivity for peficitinib 150 mg at week 12. ET early termination, MCID minimal clinically important difference, WPAI Work Productivity and Activity Impairment

Back to article page